Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 122
- https://doi.org/10.3389/fonc.2013.00122
Abstract
The crucial role of HER2 in epithelial transformation and its selective overexpression on cancer tissues makes it an ideal target for cancer immunotherapies such as passive immunotherapy with Trastuzumab. There are, however, a number of concerns regarding the use of monoclonal antibodies which include resistance, repeated treatments, considerable costs, and side effects that make active immunotherapies against HER2 desirable alternative approaches. The efficacy of anti-HER2 DNA vaccination has been widely demonstrated in transgenic cancer-prone mice, which recapitulate several features of human breast cancers. Nonetheless, the rational design of a cancer vaccine able to trigger a long-lasting immunity, and thus prevent tumor recurrence in patients, would require the understanding of how tolerance and immunosuppression regulate antitumor immune responses and, at the same time, the identification of the most immunogenic portions of the target protein. We herein retrace the findings that led to our most promising DNA vaccines that, by encoding human/rat chimeric forms of HER2, are able to circumvent peripheral tolerance. Preclinical data obtained with these chimeric DNA vaccines have provided the rationale for their use in an ongoing Phase I clinical trial (EudraCT 2011-001104-34).Keywords
This publication has 36 references indexed in Scilit:
- Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)PLOS ONE, 2013
- CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor modelCancer Gene Therapy, 2011
- Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to HumansCancers, 2011
- 2011: the immune hallmarks of cancerCancer Immunology, Immunotherapy, 2011
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialJournal of Translational Medicine, 2010
- Erbb2 DNA Vaccine Combined with Regulatory T Cell Deletion Enhances Antibody Response and Reveals Latent Low-Avidity T Cells: Potential and Limits of Its Therapeutic EfficacyThe Journal of Immunology, 2010
- Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical DevelopmentsMolecular Therapy, 2009
- Immunosurveillance ofErbb2Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-ToleranceCancer Research, 2006
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003